Eli Lilly stock: Wells Fargo maintains Buy rating for Eli Lilly stock at USD 1,330.00

Published on 10/16/2026 at 17:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are scheduled for October 29, 2026. Eli Lilly stock costs EUR 1,131.70 on October 16, 2026, plus 0.06 percent versus the Xetra close.

Analyst target and results date

On October 15, 2026, Wells Fargo kept its Buy rating and set a USD 1,330.00 target for Eli Lilly stock.
Eli Lilly will announce its third-quarter 2026 results on October 29, 2026.
Eli Lilly stock costs EUR 1,131.70 at Lang & Schwarz on October 16, 2026 at 5:13 p.m. CEST, plus 0.06 percent versus the Xetra close of October 16, 2026.
Eli Lilly had a price-to-earnings ratio of 42.42 as of October 16, 2026.

Pop-Art-Comicillustration eines Wissenschaftlers mit Spritze und Insulinpen im Labor — Pop-Art-Comicszene mit Wissenschaftler symbolisiert Eli Lilly and Company, ISIN US5324571083, kreativ im Pharmabereich humorvoll, Illustration mit AI erstellt.

Wells Fargo maintained its Buy rating for Eli Lilly and set a USD 1,330.00 price target on October 15, 2026, according to Markets Insider. The target is 5.17 percent above the USD 1,264.59 home-market price. At Lang & Schwarz, Eli Lilly was trading at EUR 1,131.70 on October 16, 2026 at 5:13 p.m. CEST, plus 0.06 percent versus the Xetra close of October 16, 2026 at EUR 1,131.00.

October 29 results date

Eli Lilly will announce its third-quarter 2026 financial results on October 29, 2026. The company confirmed the date and a conference call in a release dated October 15, 2026, published by Eli Lilly and Company. The call is scheduled for 10:00 a.m. Eastern time.

What does the target imply?

The Wells Fargo target sits above the latest home-market price, while the latest reported quarter already supplied a substantial earnings base. Revenue reached USD 22.97 billion and net profit was USD 7.10 billion in the second quarter of 2026, compared with USD 15.56 billion and USD 5.66 billion in the second quarter of 2025, respectively, according to Markets Insider. The comparison puts the target discussion alongside a clearly stronger year-over-year operating base.

Price position and valuation

The USD 1,264.59 home-market price stood 2.17 percent below the USD 1,292.65 52-week high and 61.33 percent above the USD 783.85 low as of October 16, 2026. The stock was up 12.47 percent year to date on the same date. Market capitalization was USD 1.2 trillion, while the price-to-earnings ratio was 42.42.

Comparison with peers

Eli Lilly and Co.: plus 0.06 percent, P/E 42.42, market capitalization USD 1.2 trillion, as of October 16, 2026.

Novo Nordisk A/S (NYSE, USD): minus 0.36 percent, P/E 9.91, market capitalization USD 174.3 billion, as of October 16, 2026.

Merck & Co., Inc. (NYSE, USD): plus 1.18 percent, P/E 117.59, market capitalization USD 362.4 billion, as of October 16, 2026.

Trading after the Xetra close

The euro quotation remained close to the Xetra closing level after the regular German session. The latest market picture combines a USD 1,330.00 Wells Fargo target, a USD 1.2 trillion market capitalization and the scheduled October 29 results date. The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.